Ferran Fece de la Cruz, Instructor in Medicine at Harvard Medical School and Massachusetts General Hospital, shared a post on X about a recent article he and his colleagues co-authored, adding:
“Happy to report the first clinical evidence revealing how tumors develop resistance to p53-Y220C reactivators out today.”
Title: Acquired on-target alterations drive clinical resistance to p53-Y220C reactivators
Authors: Ferran Fece de la Cruz, Andreas Varkaris, Parasvi S. Patel, Elijah W. Kushner, Alvin A. Morales-Giron, Sangmi Sandra Lee, Ankit Singh, Clara T. Kim, Bryanna L. Norden, Sara Ehnstrom, Jakob M. Riedl, Jacquelyn M. Curtis, Haley Barnes, Allison M. Kehlmann, Nicholas J. Chevalier, Hitomi S. Okuma, Manisha Patel, Lori J. Wirth, Brendan Connell, Francis Nugent, Leontios Pappas, Kayao Lau, Dejan Juric, Jessica L. Hopkins, Keelan Z. Guiley, Kevan M. Shokat, Doga C. Gulhan, Aparna R. Parikh, Ryan B. Corcoran
Read the Full Article on Cancer Discovery
More posts featuring Cancer Resistance.